← All trials
NCT00265850
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2005
- Primary completion
- Feb 1, 2015
- Completion date
- Dec 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 2334
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- National Cancer Institute (NCI)Lead sponsor
- Aptuit Inc.Collaborator
- University of California, San FranciscoStudy chair
- National Cancer Institute (NCI)Collaborator
- Southwest Oncology GroupCollaborator
- Bristol-Myers SquibbCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.